This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Biotech Calendar: Key Dates for September

Stocks in this article: CLSN EXEL VRTX DVAX AMRN DCTH ASTM

BOSTON ( TheStreet) -- A calendar of important, potentially stock-moving biotech events for September:

Sept. 7
Hospira (HSP) investor/analyst meeting.

Sept. 7-8
Baird 2011 Healthcare Conference

Sept. 8
FDA advisory panel meeting to review Johnson & Johnson's (JNJ) Xarelto for the prevention of strokes and blood clots in patients with atrial fibrillation.

Sept. 9
FDA advisory panel meeting to review the benefits and risks of long-term use of bisphosphonates to treat osteoporosis in light of safety concerns related to jawbone death and unusual thigh-bone fractures. Drugs to be examined include Merck's (MRK) Fosamax, Novartis' (NVS) Reclast, Warner Chilcott's (WCRX) Actonel and Roche's (RHHBY) Boniva.

Sept. 11-13
Rodman & Renshaw Global Investment Conference

Sept. 12
Delcath Systems (DCTH) presenting data from phase II study in neuroendocrine tumors at the Cardiovascular and Interventional Radiology Society of Europe meeting.

Sept. 14
FDA advisory panel to discuss development and possible clinical trial design of products for the treatment of patients with non-metastatic castration resistant prostate cancer (CRPC) who have a rising serum level of prostate-specific antigen (PSA) despite being on androgen deprivation therapy (ADT). There are no drugs currently approved for this indication and no specific drugs will be presented or discussed. The FDA's experts will consider possible trial designs and suitable clinical endpoints to establish efficacy that would support approval of a drug for the treatment of non-metastatic CRPC after PSA progression on ADT.

Companies with possible interest in this segment of prostate cancer therapy include Dendreon (DNDN), Exelixis (EXEL), Medivation (MDVN) and Johnson & Johnson.

Sept. 17-20
51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). Presentations include Dynavax's (DVAX) Heplisav phase III results in hepatitis B prevention on Sept. 18 and updated phase I data on Sangamo BioSciences' (SGMO) experimental HIV drug SB-728.

Sept. 18-21
Heart Failure Society of America Annual Scientific Meeting. Presentations include data from a phase II "catheter" study of Aastrom Biosciences' (ASTM) Ixmyelocel-T in patients with dilated cardiomyopathy.

Sept. 19-21
UBS Global Healthcare Conference

Sept. 23-27
European Society for Medical Oncology (ESMO) Multidisciplinary Cancer Congress

Sept. 25-27
American Neurological Association Annual Meeting

Sept. 27-28
JMP Securities Healthcare Conference

Biotech events expected before the end of September:
Chelsea Therapeutics (CHTP): Complete FDA approval filing for Northera as treatment for neurogenic orthostatic hypotension.
Amarin (AMRN): Complete FDA approval filing for AMR101 for treatment of patients with high triglyceride levels.
Celsion (CLSN): Interim analysis of phase III study of Thermodox in primary liver cancer.
Exelixis (EXEL): Top-line results of phase III study of cabozantinib in medullary thyroid cancer.
Vertex Pharmaceuticals (VRTX): Top-line results of phase II study of VX-509 in rheumatoid arthritis.
Gilead Sciences (GILD): Top-line results from phase III "103" study of experimental Quad HIV pill versus Reyataz and Truvada.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs